Theseinclude (i) reduction in the excessive hepatic glucose production(Glucagon, Hexokinase, G6P, F16BP, GSK3β); (ii) increasedglucose-stimulated insulin secretion (DPP-IV inhibitors, GLP-1and GLP-1 receptor agonists); (iii) inhibition of specific moleculartargets involved in insulin signaling pathway (resistin, PTP1Binhibitors and SHIP2 inhibitors); (iv) control of obesity andaltered lipid metabolism (Adiponectin, AMPK and PTP1Binhibitors). The gene discussed is INS; the disease is obesity disorder.